JPH0443887B2 - - Google Patents
Info
- Publication number
- JPH0443887B2 JPH0443887B2 JP29154286A JP29154286A JPH0443887B2 JP H0443887 B2 JPH0443887 B2 JP H0443887B2 JP 29154286 A JP29154286 A JP 29154286A JP 29154286 A JP29154286 A JP 29154286A JP H0443887 B2 JPH0443887 B2 JP H0443887B2
- Authority
- JP
- Japan
- Prior art keywords
- dihydroxyvitamin
- cataracts
- vitamin
- cataract
- crystalline lens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000002177 Cataract Diseases 0.000 claims description 18
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims description 3
- FCKJYANJHNLEEP-OIMXRAFZSA-N 24,25-Dihydroxyvitamin D Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C FCKJYANJHNLEEP-OIMXRAFZSA-N 0.000 claims description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 2
- 210000000695 crystalline len Anatomy 0.000 description 15
- 239000011575 calcium Substances 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 229920000818 Catalin Polymers 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N Pirenoxine Chemical compound C12=NC3=CC=CC=C3OC2=CC(=O)C2=C1C(=O)C=C(C(=O)O)N2 OKPNYGAWTYOBFZ-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- XFQYJNINHLZMIU-UHFFFAOYSA-N cataline Natural products CN1CC(O)C2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 XFQYJNINHLZMIU-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- SQEHCNOBYLQFTG-UHFFFAOYSA-M lithium;thiophene-2-carboxylate Chemical compound [Li+].[O-]C(=O)C1=CC=CS1 SQEHCNOBYLQFTG-UHFFFAOYSA-M 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 201000008525 senile cataract Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29154286A JPS63145233A (ja) | 1986-12-09 | 1986-12-09 | 白内障治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29154286A JPS63145233A (ja) | 1986-12-09 | 1986-12-09 | 白内障治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63145233A JPS63145233A (ja) | 1988-06-17 |
| JPH0443887B2 true JPH0443887B2 (de) | 1992-07-20 |
Family
ID=17770254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29154286A Granted JPS63145233A (ja) | 1986-12-09 | 1986-12-09 | 白内障治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63145233A (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW422696B (en) * | 1995-03-20 | 2001-02-21 | Katsuhiko Mukai | Ophthalmic composition containing active vitamin D |
| AU5347696A (en) * | 1995-11-20 | 1997-06-11 | Kiyoshi Kita | External preparation containing vitamin d or vitamin k |
| WO1998053806A1 (fr) * | 1997-05-26 | 1998-12-03 | New Vision Co., Ltd. | Compositions medicinales a administration topique renfermant les vitamines d et les vitamines k |
| US6187331B1 (en) | 1997-06-10 | 2001-02-13 | New Vision Co., Ltd. | Composition for prophylaxis and/or treatment of dry syndrome comprising vitamin D |
-
1986
- 1986-12-09 JP JP29154286A patent/JPS63145233A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63145233A (ja) | 1988-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69629184T2 (de) | Verwendung von vitamin d2 oder vitamin d4-derivaten zur herstellung eines medikamentes zur behandlung des sekundären hyperparathyroidismus | |
| DE3855323T2 (de) | Galenische 2-beta-Mimetik-Formen für die per- und sublinguale Verabreichung | |
| JPS60109522A (ja) | 神経病の治療のためのビロバリド含有製剤組成物 | |
| JPH05186332A (ja) | 少なくとも２種の異なる作用物質を備えた薬剤学的製剤の製造方法と使用 | |
| AU1668599A (en) | Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration | |
| DE19858789A1 (de) | Kombination von Cerivastatin und Fibraten | |
| US5395830A (en) | Method of treating osteoporosis with 1α,24(R)-dihydroxy-22(E)-dehydro-vitamin D3 | |
| US4252797A (en) | Corticosteroid calcium compositions and treatment of rheumatic diseases therewith | |
| JPH0443887B2 (de) | ||
| US5393749A (en) | Method of treating osteoporosis with 1 α25-dihydroxy-22(E)-dehydro-vitamin D3 | |
| JPH0699310B2 (ja) | アセトアルデヒド解毒剤 | |
| EP0235090B1 (de) | In der Behandlung von Östrogeninsuffizienz zu verwendende Zusammensetzung | |
| US5472957A (en) | Chemical compounds and process | |
| US20070218030A1 (en) | Dietetic Preparation for Prevention and Treatment of Osteoporosis | |
| DE3035494A1 (de) | Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels | |
| WO1992013538A1 (en) | Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis | |
| JPS6210013A (ja) | 胃炎治療・予防剤 | |
| JP3816545B2 (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
| NZ203251A (en) | Pharmaceutical compositions containing 1alpha,25,26-trihydroxycholecalciferol | |
| US4501737A (en) | Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient to treat myodystrophia | |
| US10105375B2 (en) | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| JP2807535B2 (ja) | 白内障治療剤 | |
| US5942502A (en) | Method of treating diseases resulting from calcium metabolism disorders | |
| US4105794A (en) | Process of mitigating cholelithiasis | |
| US3773937A (en) | Method of treatment |